Albert Science International Organization

ARTICLE DESCRIPTION: 

Tamal Maity, Sounik Banerjee, Amlan Bishal, Rupajit Bhattacharjee, Satya Prasanna Das. The Diagnosis and Management of Pre-Eclampsia and Eclampsia: A Review, ASIO Journal of Pharmaceutical & Herbal Medicines Research (ASIO-JPHMR), 2016: 2(1), 21-23.

ARTICLE TYPE: Review

dids/doi No.: 12.2015-77737978

dids link:  http://dids.info/didslink/02.2016-14516413/

ABSTRACT:

The accurate cause of pre-eclampsia is not implicit. Often there are no symptoms and it may be picked up at your routine antenatal appointments when you have your blood pressure checked and urine tested. This is why you are asked to bring a urine sample to your appointments. Other important factors are the severity of the mother’s preeclampsia, whether or not it recurred, and a history of low birth weight babies. This does not mean the person will definitely develop these heart problems if he/she had preeclampsia, but for some women pregnancy can be considered a “failed stress test”, possibly unmasking other health issues. Many of the risk factors for preeclampsia and diseases affecting your blood pressure and heart are the same. They include a family history of high blood pressure, heart disease and diabetes, being overweight, problems with blood clotting, and metabolic syndrome. If there is no initial response to oral therapy or if it cannot be tolerated, control should be by repeated boluses of labetalol 50mg followed by a labetalol infusion as a first line drug. The use of a second line agent (hydralazine or nifedipine) can cause precipitate drops in blood pressure, particularly if magnesium sulphate therapy is also being administered.

Keywords: Pre-eclampsia, blood pressure, maternal and perinatal mortality, labetalol, hydralazine, nifedipine.

1. Haig D. Genetic conflicts in human pregnancy, Q Rev Biol., 1993, 68: 495-532.
2. Aernout Luttun, Peter Carmeliet. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest., 2003, 111: 600-2.
3. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia, Microvasc Res, 2008, 75: 1-8.
4. Noronha Neto C, de Souza AS, Amorim MM. Pre-eclampsia treatment according to scientific evidence, Rev Bras Ginecol Obstet, 2010, 32: 459-68.
5. Arora R, Ganguli RP, Swain S, Oumachigui A, Rajaram P. Determinants of maternal mortality in eclampsia in India, Aust N Z J Obstet Gynaecol, 1994, 34: 537-9.
6. Suhail M, Faizul Suhail M, Khan H. Role of vitamins C and E in regulating antioxidant and pro-oxidant markers in preeclampsia, J Clin Biochem Nutr., 2008, 43: 210-20.
7. Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia, Semin Nephrol, 2011, 31: 33-46.
8. Maynard SE, Venkatesha S, Thadhani R, Ananth Karumanchi SA. Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia, Pediatr Res, 2005, 57: 1R-7R.
9. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M. Human cytotrophoblasts adopt a vascular phenotype as they differentiate a strategy for successful endovascular invasion? J Clin Invest, 1997, 99: 2139-51.
10. Agarwal I, Karumanchi SA. Preeclampsia and the anti-angiogenic state, Pregnancy Hypertens, 2011, 1: 17-21.
11. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis, Physiology (Bethesda), 2009, 24: 147-58.
12. Szarka A, Rigó J Jr, Lázár L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array, BMC Immunol, 2010, 11: 59.
13. Wagner LK. Diagnosis and management of preeclampsia, Am Fam Physician, 2004, 70: 2317-24.
14. Harrington K, Carpenter RG, Goldfrad C, Campbell S. Transvaginal Doppler ultrasound of the uteroplacental circulation in the early prediction of pre-eclampsia and intrauterine growth retardation, Br J Obstet Gynaecol, 1997, 104: 674-81.
15. Costa FS, Murthi P, Keogh R, Woodrow N. Early screening for preeclampsia, Rev Bras Ginecol Obstet, 2011, 33: 367-75.
16. Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia, Trends Cardiovasc Med., 2008, 18: 186-94.
17. Chen Y. Novel angiogenic factors for predicting preeclampsia: sFlt-1, PlGF, and soluble endoglin, Open Clin Chem J, 2009, 2: 1-6.